Endocrine Abstracts

Background: An activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common observation in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in obesity, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY 3-36), might be also useful for the treatment of obesity. However, the effect of these substances on the adrenal gland is largely unknown. We directly compared the effec...

Background: Combinatory treatments with analogues of incretins might mimic the beneficial effects of bariatric surgery. We could show in the past that a combinatory treatment with PYY 3-36 and liraglutide leads to a similar body weight loss as Roux-en-Y gastric bypass (RYGB). We hypothesize that a combination of semaglutide and a modified PYY 3-36 analogue with increased selectivity for the neuropeptide Y receptor type 2 (NNC0165-1273) exceeds the weight-reducing effects of ba...

Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently accompanies obesity, posing a significant health concern. The Neuropeptide Y (NPY) system, a key player in energy metabolism regulation, has implications for liver health, yet the impact of NPY receptor antagonists remains largely unexplored. This study investigates the effects of antagonists targeting the NPY-2 receptor (Y2R) in comparison to known MASLD-beneficial substances.Me...